Printed from Voxsanity (voxsanity.com.au) — NCT07357532 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07357532
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have signed an informed consent form and are between 18 and 80 years old.
- People who have been diagnosed with limited-stage small cell lung cancer, confirmed through a tissue or cell sample.
- People whose physical functioning is rated at 0 or 1 on a standard medical performance scale, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site).
- People whose cancer has stabilised following combined or sequential chemotherapy and radiation treatment.
- People who have not previously received immune checkpoint inhibitor treatment.
- People who have tested positive for measurable residual disease (MRD) after completing concurrent chemoradiotherapy (confirm with trial site).
- People who are willing to share their medical records, imaging results, and other required materials for research, agree to attend follow-up appointments including blood sample collection at set timepoints, and consent to their data being used in future research.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have or have had another type of cancer.
- People who have an autoimmune condition that is not compatible with a type of immune therapy called a PD-L1 inhibitor.
- People who have previously taken certain targeted or anti-blood-vessel-growth therapies (such as erlotinib or bevacizumab, except when bevacizumab was given directly to a local area), participated in another cancer treatment clinical trial within 4 weeks before the first dose, or have previously been treated with paclitaxel.
- People with high blood pressure that remains uncontrolled despite appropriate medication, specifically where the top number is 140 or above or the bottom number is 90 or above.
- People with significant heart conditions, including serious heart muscle disease, a heart attack within the last 6 months, heart failure rated at a moderate-to-severe level, uncontrolled chest pain, dangerous heart rhythm problems, significant disease around the heart, or test results suggesting active heart stress or electrical conduction problems.
- People with serious uncontrolled health conditions that could affect their ability to follow the study plan, such as poorly managed diabetes, persistent infections, or significant mental health or social circumstances.
- People with abnormal blood clotting results or who are currently taking blood-thinning or clot-dissolving medications, or who have symptoms of unusual bleeding.
- People with a known inherited or acquired disorder affecting bleeding or clotting, such as haemophilia, low platelet levels, or an enlarged spleen affecting blood cells.
- People who have coughed up a significant amount of fresh blood (half a teaspoon or more per day) in the two months before joining the study.
- People who did not complete the required treatment or whose treatment plan was changed before their disease progressed.
- People who are unable to attend follow-up visits as required by the study schedule.
- People who are unable to undergo or provide the required methods of assessing treatment response, such as medical imaging.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
31 January 2026
Est. completion
26 September 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Negative conversion rate of MRD
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.